← All trials
NCT04802876
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 12, 2021
- Primary completion
- Dec 31, 2023
- Completion date
- Dec 11, 2024
- First posted
- Mar 17, 2021
- Last posted
- Aug 16, 2021
- Enrollment
- 141
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- SOLTI Breast Cancer Research GroupLead sponsor
- NovartisCollaborator
Drugs studied
Indications studied
- Adenocarcinoma of Lung
- Squamous Cell Carcinoma of Head and Neck
- Carcinoma, Ovarian Epithelial
- Urinary Bladder Neoplasms
- Breast Neoplasms
- Carcinoma
- Carcinoma, Transitional Cell
- Uterine Cervical Neoplasms
- Esophageal Neoplasms
- Carcinoma, Hepatocellular
- Histology
- Kidney Neoplasms
- Lung Neoplasms
- Melanoma
- Mesothelioma
- Ovarian Neoplasms
- Pancreatic Neoplasms
- Prostatic Neoplasms
- Rectal Neoplasms
- Sarcoma
- Stomach Neoplasms
- Thyroid Neoplasms
- Uterine Neoplasms
- Colorectal Neoplasms
- Cholangiocarcinoma
- Small Cell Lung Carcinoma
- Triple Negative Breast Neoplasms
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.